Close

Regeneron (REGN) Announces IDMC Finds Clear Efficacy for REGEN-COV in Phase 3 COVID-19 Outpatient Outcomes Trial

Go back to Regeneron (REGN) Announces IDMC Finds Clear Efficacy for REGEN-COV in Phase 3 COVID-19 Outpatient Outcomes Trial
Regeneron (NASDAQ: REGN) Delayed: 892.21 -1.78 (0.2%)
Previous Close $893.99    52 Week High $592.36 
Open $913.97    52 Week Low $325.35 
Day High $920.73    P/E 234.18 
Day Low $891.67    EPS $3.81 
Volume 153,355